Synthesis and Evaluation of

FAP inhibitors (FAPIs) Gallium-68 PET imaging cancer-associated fibroblasts (CAFs) fibroblast activation protein α (FAP-α) targeted radiopharmaceuticals

Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
14 Apr 2023
Historique:
received: 18 03 2023
revised: 08 04 2023
accepted: 12 04 2023
medline: 1 5 2023
pubmed: 28 4 2023
entrez: 28 4 2023
Statut: epublish

Résumé

Fibroblast activation protein α (FAP-α) is a cell-surface protein overexpressed on cancer-associated fibroblasts that constitute a substantial component of tumor stroma and drive tumorigenesis. FAP is minimally expressed by most healthy tissues, including normal fibroblasts. This makes it a promising pan-cancer diagnostic and therapeutic target. In the present study, we synthesized two novel tracers, [

Identifiants

pubmed: 37110717
pii: molecules28083481
doi: 10.3390/molecules28083481
pmc: PMC10145249
pii:
doi:

Substances chimiques

Gallium Radioisotopes 0
Thiazolidines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : CIHR
ID : PJT-180300
Pays : Canada

Références

Bioorg Med Chem Lett. 2012 May 15;22(10):3412-7
pubmed: 22525314
Cancer Res. 2002 Aug 15;62(16):4767-72
pubmed: 12183436
Bioorg Med Chem. 2013 Dec 1;21(23):7418-29
pubmed: 24153396
Cancer Res. 2015 Jan 15;75(2):387-93
pubmed: 25488751
J Nucl Med. 2020 Dec;61(12):1806-1813
pubmed: 32332144
Arthritis Res Ther. 2006;8(6):R171
pubmed: 17105646
Pharmaceuticals (Basel). 2021 Oct 05;14(10):
pubmed: 34681246
Mol Imaging Biol. 2021 Oct;23(5):686-696
pubmed: 33721173
Cancer Gene Ther. 2022 Aug;29(8-9):1080-1096
pubmed: 34987176
Oncogene. 2004 Jul 15;23(32):5435-46
pubmed: 15133496
J Med Chem. 2011 Jul 14;54(13):4365-77
pubmed: 21634429
Cancer Sci. 2010 Nov;101(11):2325-32
pubmed: 20804499
Bioorg Med Chem. 2004 Dec 1;12(23):6053-61
pubmed: 15519151
J Nucl Med. 2022 Jun;63(6):890-896
pubmed: 34620730
J Med Chem. 2010 Feb 25;53(4):1732-40
pubmed: 20088512
FEBS Lett. 2006 Mar 6;580(6):1581-6
pubmed: 16480718
J Nucl Med. 2018 Sep;59(9):1415-1422
pubmed: 29626119
J Med Chem. 2022 Jun 23;65(12):8245-8257
pubmed: 35658448
Expert Rev Hematol. 2015 Aug;8(4):383-5
pubmed: 25946901
J Nucl Med. 2018 Sep;59(9):1423-1429
pubmed: 29626120
J Exp Med. 2013 Jun 3;210(6):1125-35
pubmed: 23712432
Curr Opin Chem Biol. 2003 Aug;7(4):496-504
pubmed: 12941425
J Nucl Med. 2022 Jun;63(6):952-958
pubmed: 34593598
Bioorg Med Chem Lett. 2005 Oct 1;15(19):4239-42
pubmed: 16085416
Acta Pharmacol Sin. 2018 Mar;39(3):415-424
pubmed: 29119969
J Nucl Med. 2019 Oct;60(10):1421-1429
pubmed: 30850501
Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):385-389
pubmed: 34226953
J Nucl Med. 2019 Mar;60(3):386-392
pubmed: 30072500
Bioorg Med Chem Lett. 2009 Jul 15;19(14):3859-62
pubmed: 19423349
Mol Cancer Ther. 2005 Mar;4(3):351-60
pubmed: 15767544
J Nucl Med. 2019 Jun;60(6):801-805
pubmed: 30954939
Hum Pathol. 2013 Nov;44(11):2549-57
pubmed: 24074532
Hepatology. 1999 Jun;29(6):1768-78
pubmed: 10347120
Hum Pathol. 2006 Mar;37(3):352-60
pubmed: 16613331
Molecules. 2023 Jan 21;28(3):
pubmed: 36770755
Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5657-61
pubmed: 7911242
Clin Cancer Res. 2003 May;9(5):1639-47
pubmed: 12738716
J Med Chem. 2014 Apr 10;57(7):3053-74
pubmed: 24617858
J Clin Oncol. 1994 Jun;12(6):1193-203
pubmed: 8201382
J Med Chem. 2010 Sep 23;53(18):6572-83
pubmed: 20718420
PLoS One. 2015 Mar 16;10(3):e0116683
pubmed: 25775399

Auteurs

Shreya Bendre (S)

Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.

Zhengxing Zhang (Z)

Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.

Nadine Colpo (N)

Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.

Jutta Zeisler (J)

Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.

Antonio A W L Wong (AAWL)

Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.

François Bénard (F)

Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
Department of Functional Imaging, BC Cancer, Vancouver, BC V5Z 4E6, Canada.
Department of Radiology, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.

Kuo-Shyan Lin (KS)

Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
Department of Functional Imaging, BC Cancer, Vancouver, BC V5Z 4E6, Canada.
Department of Radiology, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH